14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CNEY vs BBLG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, CN Energy Group Inc. Class A (CNEY) is the stronger overall head-to-head candidate over Bone Biologics Corp (BBLG) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CNEY carries a Unified Composite Score of 35.1/100 (SELL) at $0.44 (N/M Forward P/E, -138.5% operating margin), whereas BBLG carries 45.5/100 (HOLD) at $0.29 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While BBLG currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. CNEY 35.1/100 SELL), CNEY captures the overall institutional head-to-head verdict (2–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-138.5% vs. 0.0% operating margin) and revenue trajectory (+8.2% vs. +0.0% YoY).
Technical & Structure Timing Caution: CNEY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile BBLG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNEY vs BBLG. Trailing 12-month operating profitability (CNEY -138.5% vs BBLG 0.0%) and valuation multiples (CNEY N/M vs BBLG N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CNEY vs BBLG Key Questions & Quantitative Answers
As of Nov 17, 2026, CN Energy Group Inc. Class A (CNEY) is the stronger overall head-to-head candidate over Bone Biologics Corp (BBLG) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CNEY carries a Unified Composite Score of 35.1/100 (SELL) at $0.44 (N/M Forward P/E, -138.5% operating margin), whereas BBLG carries 45.5/100 (HOLD) at $0.29 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While BBLG currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. CNEY 35.1/100 SELL), CNEY captures the overall institutional head-to-head verdict (2–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-138.5% vs. 0.0% operating margin) and revenue trajectory (+8.2% vs. +0.0% YoY). Technical & Structure Timing Caution: CNEY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile BBLG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CNEY leads the Growth & Scale pillar: CNEY posts +8.2% YoY revenue growth and +76.7% YoY earnings growth on $37M TTM revenue (1.1% gross margin, -138.5% operating margin), compared with BBLG at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CNEY generates $37M in USD-normalized revenue versus N/A for BBLG. In operating R&D and SG&A reinvestment, CNEY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BBLG.
CNEY screens cheaper on headline valuation multiples. CNEY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-136.7% EBITDA margin), whereas BBLG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNEY (-84.3% ROE) versus BBLG (-47.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CNEY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.70β · 109% Vol realized risk). By comparison, BBLG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.99β · 100% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.